Generating Actionable Data From Antimicrobial Resistance Surveillance: Insights From the Fleming Fund's International Experience

Clicks: 1
ID: 332997
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #610 of 619 articles by views in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 619 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Antimicrobial resistance (AMR) is a major global health threat, with the greatest burden falling on low- and middle-income countries (LMICs) also challenged with limited surveillance capacity. The UK Government's Fleming Fund was established in 2015 to strengthen AMR surveillance across Africa and Asia through a One Health approach. This paper draws on program experience, country implementation evidence, and published literature to describe how the Fleming Fund operationalized AMR surveillance, assess its contribution to the quantity and quality of surveillance data, identify key implementation challenges, and consider implications for future global surveillance strategies. The Fleming Fund combined investments in laboratory infrastructure, workforce development, quality assurance, data systems, governance, and data use. Across supported countries, these investments enabled substantial growth in routine bacteriology and antimicrobial susceptibility testing, strengthened reference and surveillance laboratory capacity, increased participation in external quality assessment, and expanded reporting to the World Health Organization's Global Antimicrobial Resistance and Use Surveillance System. The program also supported complementary surveillance approaches, including antimicrobial use and consumption data and, in some settings, burden-of-disease and genomic surveillance. Progress, however, has been uneven and remains vulnerable to fragile infrastructure, procurement and supply chain bottlenecks, workforce turnover, fragmented data systems, weak clinical–laboratory interfaces, limited representativeness, and uncertain long-term financing. The Fleming Fund experience shows that strengthening AMR surveillance in LMICs is feasible, but requires sustained, system-wide investment. Future strategies should prioritize integration with clinical care, stronger digital and analytical capacity, broader diagnostic access, and domestic financing to ensure that high-quality AMR data are generated, shared, and translated into action.
Reference Key
openalex_W7222922225 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Ankur Gupta‐Wright, Suliat Yetunde Adeleke, Victoria Olusola Adetunji, Qadeer Ahsan, Ritu Amatya, Ben Amos, Brian Adu Asare, Sorie I O Bangura, Cyril Buhler, Nicholas Feasey, Nicola Claire Gordon, Heidi Hopkins, Freddy Eric Kitutu, Toby J Leslie, Ibrahima Lo, Seynabou Lô, Ayodele Oluwakemi Majekodunmi, Rebecca Maudling, Ntombi Basimbi Mudenda, Victor Moses Musyoki, Deborah Nanjebe, Tessa Oakley, Manish Pathak, Tamalee Roberts, Lamiaa Shehata, Tim Shorten, Nure Alam Siddiky, John M. Stelling, Muhammad Taimoor, May Soe Thwe, Shawn Ting, Didem Törümküney, Paul Turner, Jacob Wildfire, Timothy David Worth
Journal Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Year 2026
DOI
10.1093/cid/ciag497
URL
https://doi.org/10.1093/cid/ciag497
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.